Simplex Trading
VYNT

Simplex Trading’s Vyant Bio, Inc. Common Stock VYNT Stock Holding History

Simplex Trading’s Portfolio VYNT Stock Details VYNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Hold
0
– -$5K – 6346
2015
Q3 		– Hold
0
– – – 4026
2015
Q1 		– Hold
0
– -$2K – 5787
2014
Q4 		– Hold
0
– – – 3860

Other funds holding VYNT

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
LI
Leap Investments Chicago, Illinois $152M AUM 3.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Simplex Trading's VYNT Position: Q4 2019 in Review

Simplex Trading sold out of Vyant Bio, Inc. Common Stock (VYNT) in Q4 2019, closing a stake of 1 share — an estimated $24 sold.

Simplex Trading first reported a position in VYNT in Q4 2014 and held it in 5 quarters. The position peaked at $8K in Q3 2015. 18 funds tracked by Wall St. Rank hold VYNT as of Q4 2019.

  • Simplex Trading reported no remaining Vyant Bio, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Simplex Trading sold 1 Vyant Bio, Inc. Common Stock share in Q4 2019, an estimated $24.
  • Simplex Trading first reported a position in Vyant Bio, Inc. Common Stock in Q4 2014 and held it in 5 quarters.
  • Simplex Trading's Vyant Bio, Inc. Common Stock position peaked at $8K in Q3 2015.
  • 18 funds tracked by Wall St. Rank held Vyant Bio, Inc. Common Stock as of Q4 2019.

Based on Simplex Trading's 13F filing for Q4 2019, filed 5 Feb 2020.